Fundraising Fox

Axoft

Cambridge, US · Founded 2021 · Delaware corporation · 40 employees on LinkedIn · 9 known investors

Axoft is developing soft, tissue-mimicking neural implants and supporting bidirectional electronics that record and stimulate brain activity through a minimally-invasive burr-hole procedure. The company also builds a Brain Foundation Model software to decode and interpret neural signals for brain-computer interface applications.

Also known as Axoft, Inc.

Founders & leadership

Axoft was founded in 2021 by Paul Le Floch and Tianyang Ye.

PLPaul Le Floch
Paul Le FlochinCo-founder & CEO30 Under 30 2022
TYTianyang Ye
Tianyang YeCo-founder
RS
Rachel ShaNamed on SEC filing

Board

CA
Chia An LeeBoard director
BP
Benjamin PlessBoard director

Investors · 9

Reported raises · per SEC filings

Form D private placements

$43.5M disclosed across 3 rounds · 2022–2026

$34.2MraisedMay 2026 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul Le FlochExecutive Officer, Director
  • Chia An LeeDirector
  • Benjamin PlessDirector
Offering amount
$34.2M
Amount sold
$34.2M
First sale
Apr 2026
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$8.8MraisedMar 2024 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin PlessDirector
  • Rachel ShaDirector
  • Paul Le FlochExecutive Officer, Director
  • Tianyang YeDirector
Offering amount
$9.3M
Amount sold
$8.8M
First sale
Mar 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$500KraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin PlessDirector
  • Paul Le FlochExecutive Officer, Director
  • Rachel ShaDirector
  • Tianyang YeDirector
Offering amount
$5M
Amount sold
$500K
First sale
Feb 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Company profile

researched Aug 2026

Axoft is developing an implantable neural interface built from materials engineered to mimic the mechanical properties of soft brain tissue. The company states its implant is roughly 1,000,000 times softer than conventional rigid electronics while carrying about 1,000 times the electrode density of soft implants currently on the market. The stated design intent is to reduce implant drift and long-term tissue damage while preserving high channel counts.

The system is bidirectional: signals captured by the implant are processed by an integrated circuit and passed to software for interpretation, and the software can also drive electrical stimulation of the brain through the implant. Axoft's neural probes are designed to pass through a 2 mm-diameter burr hole and to work with standard neuronavigation tools, allowing access to brain regions including deep structures. Alongside the hardware, the company is building a Brain Foundation Model, software intended to improve decoding and interpretation of neural signals over time. The stated long-term goal is durable communication with any brain region at single-neuron resolution.

Full profile — market position, technology

Market position

Axoft positions its implant on two quantitative claims: material approximately 1,000,000 times softer than today's rigid electronics, and approximately 1,000 times greater electrode density than soft implants available on the market. The combination of tissue-like softness with high electrode density is presented as the means to limit implant drift and chronic tissue damage without sacrificing recording resolution, complemented by minimally invasive insertion through a 2 mm burr hole.

Technology

The core technology combines a soft, tissue-mimicking implant material with ultra-high-density electrode arrays, an integrated circuit for on-device signal processing, and interpretation software. The material approach is intended to improve biocompatibility, data resolution and signal stability over time relative to rigid electronics. The implant supports both recording and electrical stimulation. Probes are sized to fit a 2 mm-diameter burr hole and are compatible with standard neuronavigation tools for targeting superficial or deep brain regions. Axoft is also developing an in-house Brain Foundation Model for neural signal decoding.

Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Burr hole diameter for probe insertionJan 20242 mm
Electrode density relative to soft implants on the marketJan 20241,000 x greater
Implant softness relative to rigid electronicsJan 20241,000,000 x softer

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Competitors · 6

by search overlap
Orbit6 shared keywordsOrbit is developing a brain-computer interface and accompanying models that decode emotional states. The company's goal is to make emotional context available in human interactions and in the products people use. Its investors include founders and executives from companies such as Google, Apple, Microsoft, Hugging Face, Stability AI, and Dropbox.
Blackrock Neurotech5 shared keywordsBlackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions. It builds implantable neural interface technology for medical and research applications.
Motif Neurotech5 shared keywordsMotif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression. The company builds implantable neurotechnology for patients with mental illness and is based in Houston, Texas.
Agiloft4 shared keywordsAgiloft offers a Contract Lifecycle Management (CLM) and contracts AI platform that centralizes, automates, and governs the contract process from request and negotiation through execution, obligation tracking, and renewal. It serves legal, procurement, finance, sales, and IT teams at enterprises, converting agreements into searchable, queryable data for risk analysis and business intelligence.
Coherence Neuro4 shared keywordsCoherence develops neurotechnology systems that measure and modulate brain activity to treat cancer and other neurological diseases. The company uses bioelectronic interfaces and AI to decode the body's neural signals and enable precise, adaptive therapeutic interventions.
Precision4 shared keywordsPrecision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts. The company works with hospital clinical partners on implanted studies and positions its technology as removable and upgradable without damaging the brain.

Companies competing with Axoft for the same Google search keywords, organic and paid, via search-intersection analysis.

Legal entities · 1

corporate structure
AxoftDelaware

In the news

Research sources · 1

primary sources listed

1 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Axoft do?
Axoft develops a soft, bioinspired brain implant designed for long-term, high-density neural recording and stimulation.
Who founded Axoft?
Axoft was founded by Paul Le Floch, Tianyang Ye in 2021.
Who are Axoft's investors?
Axoft's investors include Archerman Capital, Blindspot Ventures Management Co, Castor Ventures (an Alumni Ventures Fund), Creative Destruction Lab (CDL), Safar Partners, The Engine Ventures, Alumni Ventures, Gaorong Ventures and 1 more.
How much funding has Axoft raised?
Axoft has disclosed $43.5M raised across 3 rounds.
Where is Axoft headquartered?
Axoft is headquartered in Cambridge, US.